Aptevo Therapeutics Inc (NASDAQ:APVO) Director Fuad El-Hibri purchased 100,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was bought at an average price of $0.76 per share, for a total transaction of $76,000.00. Following the acquisition, the director now owns 1,124,536 shares in the company, valued at $854,647.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Fuad El-Hibri also recently made the following trade(s):

  • On Monday, July 29th, Fuad El-Hibri bought 55,015 shares of Aptevo Therapeutics stock. The stock was acquired at an average cost of $0.83 per share, for a total transaction of $45,662.45.
  • On Monday, July 22nd, Fuad El-Hibri bought 30,000 shares of Aptevo Therapeutics stock. The stock was acquired at an average cost of $0.89 per share, for a total transaction of $26,700.00.
  • On Thursday, July 18th, Fuad El-Hibri bought 14,404 shares of Aptevo Therapeutics stock. The stock was acquired at an average cost of $0.87 per share, for a total transaction of $12,531.48.
  • On Tuesday, July 16th, Fuad El-Hibri bought 11,375 shares of Aptevo Therapeutics stock. The stock was acquired at an average cost of $0.85 per share, for a total transaction of $9,668.75.
  • On Wednesday, July 10th, Fuad El-Hibri bought 18,919 shares of Aptevo Therapeutics stock. The stock was acquired at an average cost of $0.85 per share, for a total transaction of $16,081.15.

Shares of APVO stock traded down $0.04 during mid-day trading on Tuesday, reaching $0.73. The company’s stock had a trading volume of 625,079 shares, compared to its average volume of 580,831. The firm’s 50 day moving average is $0.88. Aptevo Therapeutics Inc has a 12-month low of $0.49 and a 12-month high of $5.80. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.15 and a quick ratio of 2.91. The stock has a market cap of $32.71 million, a price-to-earnings ratio of -0.30 and a beta of 2.39.

Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Friday, August 9th. The biotechnology company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.03. Aptevo Therapeutics had a negative net margin of 195.95% and a negative return on equity of 137.50%. The business had revenue of $7.36 million for the quarter, compared to the consensus estimate of $6.95 million. On average, equities research analysts predict that Aptevo Therapeutics Inc will post -1.4 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in APVO. Acadian Asset Management LLC increased its stake in Aptevo Therapeutics by 312.8% during the 2nd quarter. Acadian Asset Management LLC now owns 632,507 shares of the biotechnology company’s stock worth $560,000 after buying an additional 479,278 shares during the period. Renaissance Technologies LLC increased its stake in Aptevo Therapeutics by 32.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,644,856 shares of the biotechnology company’s stock worth $1,458,000 after buying an additional 406,930 shares during the period. Deutsche Bank AG increased its stake in Aptevo Therapeutics by 251.7% during the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after buying an additional 236,300 shares during the period. Bank of New York Mellon Corp increased its stake in Aptevo Therapeutics by 256.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 56,620 shares of the biotechnology company’s stock worth $50,000 after buying an additional 40,728 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Aptevo Therapeutics during the 1st quarter worth $33,000. 36.37% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently commented on APVO shares. Roth Capital reissued a “buy” rating on shares of Aptevo Therapeutics in a research note on Thursday, May 23rd. ValuEngine raised shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Piper Jaffray Companies raised their target price on shares of Aptevo Therapeutics from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, April 15th. Finally, Zacks Investment Research raised shares of Aptevo Therapeutics from a “sell” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Tuesday. Five research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $7.81.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Read More: How to use beta for portfolio diversification

Insider Buying and Selling by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.